Aldevron expands antibody development facility in Freiburg, Germany

Aldevron, a US-based contract development and manufacturing organisation (CDMO), has unveiled plans to expand its antibody development facility located in Freiburg, Germany.

The Freiburg site, which houses the GENOVAC antibody development platform, has been a significant part of Aldevron‘s operations since 2004, marking the company’s second site. The expansion is driven by increasing demand and the company’s need to scale its operations to support its growing customer base globally. According to Michael Chambers, Aldevron’s Founding Partner and CEO, the move is a strategic investment to enhance the company’s ability to provide high-quality antibody generation using advanced genetic immunization strategies.

Expansion to Meet Growing Demand for Antibody Development

Michael Chambers emphasised that Aldevron has experienced a “marked increase in demand” for its services, prompting the expansion of the Freiburg facility. He noted that the company has been providing transformative antibody development solutions for more than 15 years, serving clients worldwide across various target types. The expansion is intended to better serve an ever-growing industry, which is tackling some of the world’s most significant health challenges.

The expansion will see an additional 4,300 square feet of laboratory and production space being added to the existing facility. This move will immediately create room for more personnel and equipment, increasing capacity for cell culture, fusion, production, and sequencing. Moreover, Aldevron plans to introduce new services later in the year, further enhancing its portfolio and service offerings.

Investment in the Future of Biotech

Aldevron’s expansion of its Freiburg site underscores the growing importance of antibody development within the global biotechnology industry. As the company continues to innovate and evolve, the increased capacity will position Aldevron as a key player in meeting the global demand for antibody solutions. The expansion also reflects the company’s commitment to scaling its operations to address some of the most pressing health challenges faced by the world today.

This investment solidifies Aldevron’s place as a leading provider of antibody development services and showcases the company’s ongoing commitment to excellence in the pharmaceutical industry.